New drug testing guidelines
In response to changing mandatory guidelines for federal workplace drug testing in the US, Agilent Technologies and South Bend Medical Foundation have developed new urine testing methods.
In response to changing mandatory guidelines for federal workplace drug testing in the US, Agilent Technologies and South Bend Medical Foundation have developed new urine testing methods. For the first time, the guidelines will allow for the use of liquid chromatography–triple quadrupole mass spectrometry (LC–MS–MS) for confirmatory urine drug testing.
“We frequently hear that the main barriers to adopting the new technologies required to drive laboratory productivity and/or cost reductions are lack of time and in-house expertise,” said Tom Gluodenis, Jr, Agilent worldwide forensics programme manager. “The tools we have just developed in response to the changing workplace guidelines could enable laboratories to validate these methods and be running billable urine confirmations in under 60 days.”
Use of LC–MS–MS for urine drug confirmations is reported to speed testing and reduce cost-per-sample compared with previous methods. In addition, several new target drugs have been added to the panel, several cut‑off concentrations have been adjusted, and the minimum requirements for interference testing have been satisfied for amphetamines and opiates. Also, the new requirement specifying at least 10 data points across a peak can be met.
For more information visit www.agilent.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
